26 April 2025 in Meditsinskiy sovet = Medical Council
Introduction. In the context of iron deficiency states in women of reproductive age and, as a result during pregnancy, leads to the formation of the gestational complications and negatively perinatal outcomes. The routine screening for the detection of iron deficiency by determining the level of ferritin allows you to formed risk groups in order to carry out timely correction.Aim. To estimate the level and rate of an iron deficiency state in pregnant women in the first trimester.Materials and methods. The study included 401 pregnant women under surveillance in the period from January to June 2023. The main group was 134 patients with a diagnosis of iron deficiency – 33.4% of the total number of examined. The comparison group is represented by 36 pregnant women with the level of serum ferritin 41 – 60 ug/l.Results. The mean age and gestation of patients in the main and control groups were 27.9 (6.1) and 28.7 (6.8) years and 10.7 (1.9) and 10.6 (1.8) weeks, respectively. The serum ferritin level was 20.57 ± 8.83 ug/l in the patients of the main group and was significantly lower compared to the control group 49.74 ± 6.96 ug/l (p = 0.01). Among the patients in the main group, more than 80% had severe absolute iron deficiency (SF concentration < 15 ug/l), detected in 29.1% of women (39/134) and absolute iron deficiency (SF concentration ≥ 15 – < 30 ug/l) – 52.9% of cases (71/134). Features of the observation showed that in the 2nd trimester of pregnancy in patients with iron deficiency, the diagnosis of anemia was detected 2.6 times more often – 31.3% (42/134) compared to the control group.Conclusions. Determination of serum ferritin allows to identify patients with iron deficiency and timely prescribe iron preparations in preventive/therapeutic doses to reduce the frequency of perinatal and maternal complications.
10 January 2025 in Obstetrics, Gynecology and Reproduction
According to the current concept, juvenile arthritis with a systemic onset (systemic juvenile idiopathic arthritis, sJIA) and adultonset Still's disease (ASD) are considered as rare autoinflammatory diseases, with the underlying immunopathogenesis being based on the mechanisms bridging both of such diseases. Despite they develop in childhood and young age, the issues of reproduction occurring during these pathologies virtually unexplored. The article presents a clinical case of maternal death in a 22-year-old primiparous woman and analyzes the tactics of sJIA management, which was complicated by pregnancy-related macrophage activation syndrome.
1 January 2022 in Obstetrics and gynecology: News, Opinions, Training
SFSamara State Medical University of the Ministry of Health of the Russian Federation
Samara State Medical University of the Ministry of Health of the Russian Federation
+15
Обзор предложений к новой версии клинических рекомендаций
20 November 2025 in Meditsinskiy sovet = Medical Council
Introduction . The choice of medications for the treatment of iron deficiency anemia (IDA) in a pregnant woman is based on therapeutic efficacy and safety, forming a high patient compliance to long-term therapy Aim . To evaluate the therapeutic efficacy, clinical tolerance and safety of using a medication based on iron sulfate and ascorbic acid in the treatment of iron deficiency anemia in pregnant women Materials and methods . The study included 155 women diagnosed with IDA: twenty-four pregnant women in the first trimester (group 1), forty-five pregnant women in the second trimester (group 2), and eighty-six patients in the third trimester (group 3). Antianemic therapy was administered to all pregnant women with Sorbifer Durules (iron sulfate 100 mg of iron sulfate and 60 mg of ascorbic acid) 100 mg two times per day for a long time until normalization of hematological parameters and improvement of the clinical symptoms with a transition to 100 mg per day until delivery for the purpose of preventing IDA. Results. The gestational age included in the observation were 10.6 (1.6), 20.2 (2.6) and 30.9 (2.6) weeks. When analyzing hematological parameters changes in 1 month after the start of therapy, there was positive dynamic which revealed the increase in hemoglobin levels by 5.4 g/l and 7.2 g/l in patients of groups 1 and 2, respectively (p < 0.05), with a continuing tendency to increase at 37.1 ± 1.1 weeks by 10.3 g/l and 9.7 g/l (p < 0.05). It was noted that there was a decrease in the number of patients with IDA in group 1to 20.8%, which is 1.5 and 2.1 times lower compared to groups 2 and 3 (p = 0.03). Adverse reactions when taking Sorbifer Durules were registered in 3.2% of pregnant women, there were no clinical situations requiring discontinuation of the medication. Conclusion. The combination of iron sulfate and ascorbic acid in a prolonged release formula (Sorbifer Durules) is a well-tolerated and effective treatment option of IDA at any stage of pregnancy.
1 January 2022 in Russian Bulletin of Obstetrician-Gynecologist
31 May 2026 in Meditsinskiy sovet = Medical Council
Introduction. Therapy for iron deficiency conditions that complicate pregnancy, childbirth, and the postpartum period is always considered from the standpoint of the relationship between the safety and effectiveness of the medication, forming the patient’s commitment to long-term treatment. Aim. To analyze the therapeutic efficacy, clinical tolerance and perinatal outcomes when using a ferrous sulfate medication and Ascorbic acid in the treatment of iron deficiency anemia (IDA) in pregnant women. Materials and methods. The study included 61 women diagnosed with mild IDA in the first half of pregnancy (main group). The medication for treatment of Iron deficient anemia was used Sorbifer Durules (iron sulfate 100 mg Fe 2+ and Ascorbic acid 60 mg) 100 mg two times per day, until the normalization of hematological parameters and improvement of the clinical picture, with a transition to 100 mg per day until delivery to prevent IDA. The control group included 43 pregnant women without IDA. Results. The gestational age included in the observation was 14.9 (3.9) weeks. The positive dynamics were revealed an increase in hemoglobin levels by 6.3 g/l (p < 0.05) after one month of the therapy with further increase in hemoglobin at the end of the third trimester of pregnancy (36.9 ± 1.0 week) by 10.4 g/l (p < 0.05). A decrease in hemoglobin levels to 109.2 ± 6.5 and 114.1 ± 8.4 g/l was noted in patients of the main and control groups after delivery, while maintaining average parameters within the physiological values for the first week of the postpartum period (more than 100 g/l). Adverse events during treatment were recorded in 4.9% of pregnant women; there were no clinical cases requiring cessation of medication. Conclusion. Clinical data and hematological parameters during therapy with a combination of Ferrous sulfate and Ascorbic acid in an extended-release formula (Sorbifer Durules) in pregnant women demonstrated good tolerance and efficacy in the treatment of iron deficiency anemia.